ImmuCell (ICCC) Earnings Analysis

ImmuCell (ICCC) next reports earnings on 2026-08-13, consensus EPS 0.05 USD. Last quarter (2026-05-14) it beat with EPS 0.21 USD vs 0.05 USD est (+320%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -186.12.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ICCC next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate0.05 USD
Revenue estimate0.01B

ICCC earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-140.21 USD0.05 USD+320%Beat
2026-03-04-0.31 USD-0.01 USD-3000%Miss
2025-11-13-0.02 USDn/an/an/a
2025-08-140.06 USDn/an/an/a
2025-05-140.16 USDn/an/an/a

Beat rate: 1/2 (50%) over reported quarters with consensus data.

ICCC valuation and analyst view

Trailing P/E-186.12
Trailing EPS-0.06029 USD
Price / book3.46
Dividend yield0.00%
Market cap0.10B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is ImmuCell (ICCC)'s next earnings date?

ImmuCell is next scheduled to report on 2026-08-13, with a consensus EPS estimate of 0.05 USD and revenue estimate of 0.01B.

Did ICCC beat earnings last quarter?

In its 2026-05-14 report, ICCC posted EPS of 0.21 USD versus a 0.05 USD estimate — a beat of 320%.

What is ICCC's earnings track record?

Over the last 2 reported quarters with consensus data, ICCC beat estimates 1 times (50%).

What is ICCC's current P/E ratio and EPS?

ICCC trades at a trailing P/E of -186.12 on trailing EPS of -0.06029232663315416 USD.

What do analysts rate ICCC?

ICCC has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.